Pancreatic Cancer Research

ResearcherUniversal Scientific Education and Research NetworkActive in the last 2 years

Nicola Silvestris

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7814-7318; OpenAlex author ID A5078984873, A5086984759. Sources: OpenAlex.

Their work

Papers
35 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
101
Papers, trials and grants by year

2012: 1 paper · 2013: 3 papers · 2014: none · 2015: 1 paper · 2016: 3 papers · 2017: 2 papers · 2018: 3 papers · 2019: 7 papers · 2020: 5 papers · 2021: 3 papers · 2022: 2 papers · 2023: 3 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 35

  1. Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+ and S100A8+ myeloid subsets in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.clim.2026.110665↗
  2. Hereditary Pancreatic Cancer: Genetic Risk, Surveillance Strategies, and Therapeutic Implications. Co-author DOI 10.3390/ijms27146404↗
  3. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  4. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. First author DOI 10.1016/j.modpat.2023.100251↗
  5. Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment. Co-author DOI 10.3390/cancers15051454↗
  6. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metas… Co-author DOI 10.1007/s00428-021-03205-3↗
  7. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Co-author DOI 10.1016/j.critrevonc.2021.103571↗
  8. Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società I… Co-author DOI 10.1016/j.esmoop.2021.100155↗
  9. Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Co-author DOI 10.3390/biomedicines9040373↗
  10. Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights. Co-author DOI 10.3390/cancers14010005↗
  11. Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma? First author DOI 10.1097/mpa.0000000000001449↗
  12. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Co-author DOI 10.1177/1758835920947970↗
  13. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by th… Co-author DOI 10.3390/cancers12061681↗
  14. Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB technique, MRgRT, Particle Therapy, Immunotherapy and Clinical … Co-author DOI 10.3390/cancers12071729↗
  15. Hydroxy-Propil-β-Cyclodextrin Inclusion Complexes of two Biphenylnicotinamide Derivatives: Formulation and Anti-Proliferative Activity Evaluation in Pancreatic… Co-author DOI 10.3390/ijms21186545↗
  16. Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells. Co-author DOI 10.1038/s41598-019-40637-z↗
  17. Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma: Could Surgery Represent a Therapeutic Option? Last author DOI 10.20944/preprints201908.0278.v1↗
  18. Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to Mesenchyma… Co-author DOI 10.3390/cancers11010113↗
  19. CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. Last author DOI 10.3390/cancers11030330↗
  20. Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in … Last author DOI 10.3390/cancers11060749↗
  21. Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Ta… Co-author DOI 10.3390/cancers11070942↗
  22. Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers11111718↗
  23. Mast cells and angiogenesis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10238-018-0493-6↗
  24. The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer. Co-author DOI 10.1016/j.cytogfr.2018.01.007↗
  25. Focus on pancreatic cancer. Co-author DOI 10.1016/j.dld.2018.09.003↗
  26. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.critrevonc.2017.01.015↗
  27. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? Co-author DOI 10.1016/j.critrevonc.2017.03.025↗
  28. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.critrevonc.2015.11.016↗
  29. Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. Last author DOI 10.18632/oncotarget.10765↗
  30. Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.2147/ott.s106496↗
  31. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Last author DOI 10.18632/oncotarget.4492↗
  32. Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line mo… Co-author DOI 10.1007/s00520-013-1944-y↗
  33. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Co-author DOI 10.1016/j.molonc.2012.10.002↗
  34. Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Last author DOI 10.3390/ijms141019731↗
  35. Combined modality treatments in pancreatic cancer. Co-author DOI 10.1517/14728222.2012.662959↗

Closest collaborators

The 25 strongest of 101 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Oronzo Brunetti · 18 shared papers, 2015–2026 · strength 1.79
  2. Amalia Azzariti · 10 shared papers, 2013–2026 · strength 0.88
  3. Letizia Porcelli · 8 shared papers, 2013–2026 · strength 0.80
  4. Aldo Scarpa · 9 shared papers, 2013–2023 · strength 0.72
  5. Michèle Milella · 5 shared papers, 2020–2023 · strength 0.62
  6. Antonella Argentiero · 6 shared papers, 2018–2021 · strength 0.58
  7. Rosa Maria Iacobazzi · 6 shared papers, 2016–2021 · strength 0.54
  8. Claudio Luchini · 4 shared papers, 2019–2023 · strength 0.48
  9. Giuseppe Malleo · 4 shared papers, 2019–2023 · strength 0.45
  10. Antonio Giovanni Solimando · 4 shared papers, 2019–2021 · strength 0.43
  11. Massimo Falconi · 4 shared papers, 2016–2022 · strength 0.40
  12. Afshin Derakhshani · 2 shared papers, 2021–2026 · strength 0.37
  13. Vito Racanelli · 2 shared papers, 2021–2026 · strength 0.37
  14. Behzad Baradaran · 2 shared papers, 2021–2026 · strength 0.37
  15. Michele Reni · 5 shared papers, 2015–2022 · strength 0.37
  16. Enrico Vasile · 4 shared papers, 2017–2022 · strength 0.37
  17. Rita Teresa Lawlor · 3 shared papers, 2019–2023 · strength 0.33
  18. Roberto Salvia · 3 shared papers, 2019–2023 · strength 0.33
  19. Riccardo Memeo · 2 shared papers, 2019–2026 · strength 0.32
  20. Matteo Fassan · 2 shared papers, 2023 · strength 0.28
  21. Αναστάσιος Γκουντάκος · 2 shared papers, 2023 · strength 0.28
  22. Michele Simbolo · 2 shared papers, 2023 · strength 0.28
  23. Desirèe Speranza · 1 shared paper, 2026 · strength 0.26
  24. Mariapia Marafioti · 1 shared paper, 2026 · strength 0.26
  25. Antonio Pea · 2 shared papers, 2022–2023 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.